Summary of Study ST002554

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001646. The data can be accessed directly via it's Project DOI: 10.21228/M8XX43 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002554
Study TitleUntargeted lipidomic analysis of blood plasma samples from drug-naïve patients with bipolar disorder and schizophrenia
Study TypeUntargeted lipidomic analysis
Study SummaryIn this study, we obtained a lipidomic profile of plasma samples from patients with schizophrenia (SZ) and bipolar disorder (BD) in comparison to healthy controls (CT). The sample cohort consisted of 60 drug-naïve patients and 30 control individuals. Untargeted lipidomics strategy using liquid chromatography coupled to high resolution mass spectrometry was employed to obtain the data, and univariate and multivariate statistical tools were applied to evaluate the results. Metabolic pathway networks were constructed and our results demonstrated alterations in different lipid pathways, such as glycerophospholipids, sphingolipids, and prostaglandins between schizophrenia and bipolar disorder patients. The differential diagnosis is crucial for effective treatment and improving the quality of life of patients with psychotic disorders.
Institute
University of Campinas
DepartmentInstitute of Chemistry
LaboratoryLaBIOmics - Laboratory of Bioanalytics and Integrated Omics
Last NameBrixner Riça
First NameLarissa
AddressLaboratório B-211 a 215 - Instituto de Química, R. Josué de Castro, 126-336 - Cidade Universitária, Campinas - SP
Emaillarissabrixner@gmail.com
Phone+55 19 35213060
Submit Date2023-04-04
Num Groups3
Total Subjects90
Num Males42
Num Females48
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2023-06-25
Release Version1
Larissa Brixner Riça Larissa Brixner Riça
https://dx.doi.org/10.21228/M8XX43
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001646
Project DOI:doi: 10.21228/M8XX43
Project Title:Untargeted lipidomic analysis of blood plasma samples from drug-naïve patients with bipolar disorder and schizophrenia
Project Type:Untargeted lipidomic analysis
Project Summary:In this study, we obtained a lipidomic profile of plasma samples from patients with schizophrenia (SZ) and bipolar disorder (BD) in comparison to healthy controls (CT). The sample cohort consisted of 60 drug-naïve patients and 30 control individuals. Untargeted lipidomics strategy using liquid chromatography coupled to high resolution mass spectrometry was employed to obtain the data, and univariate and multivariate statistical tools were applied to evaluate the results. Metabolic pathway networks were constructed and our results demonstrated alterations in different lipid pathways, such as glycerophospholipids, sphingolipids, and prostaglandins between schizophrenia and bipolar disorder patients.
Institute:University of Campinas
Department:Institute of Chemistry
Laboratory:LaBIOmics - Laboratory of Bioanalytics and Integrated Omics
Last Name:Brixner Riça
First Name:Larissa
Address:Laboratório B-211 a 215 - Instituto de Química, R. Josué de Castro, 126-336 - Cidade Universitária, Campinas - SP
Email:larissabrixner@gmail.com
Phone:+55 19 35213060

Subject:

Subject ID:SU002654
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Age Or Age Range:15-38
Gender:Male and female
Human Exclusion Criteria:Subjects with other psychiatric or neurological disorders were excluded

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Group
SA256483BD10BD
SA256484BD09BD
SA256485BD11BD
SA256486BD13BD
SA256487BD14BD
SA256488BD08BD
SA256489BD12BD
SA256490BD07BD
SA256491BD03BD
SA256492BD02BD
SA256493BD04BD
SA256494BD05BD
SA256495BD06BD
SA256496BD15BD
SA256497BD17BD
SA256498BD26BD
SA256499BD25BD
SA256500BD27BD
SA256501BD28BD
SA256502BD30BD
SA256503BD29BD
SA256504BD24BD
SA256505BD23BD
SA256506BD18BD
SA256507BD01BD
SA256508BD19BD
SA256509BD20BD
SA256510BD21BD
SA256511BD16BD
SA256512BD22BD
SA256513CT01Control
SA256514CT10Control
SA256515CT11Control
SA256516CT12Control
SA256517CT14Control
SA256518CT13Control
SA256519CT09Control
SA256520CT08Control
SA256521CT02Control
SA256522CT30Control
SA256523CT03Control
SA256524CT04Control
SA256525CT07Control
SA256526CT05Control
SA256527CT15Control
SA256528CT06Control
SA256529CT26Control
SA256530CT24Control
SA256531CT27Control
SA256532CT28Control
SA256533CT29Control
SA256534CT16Control
SA256535CT23Control
SA256536CT25Control
SA256537CT19Control
SA256538CT22Control
SA256539CT20Control
SA256540CT21Control
SA256541CT17Control
SA256542CT18Control
SA256543QC_2_4QC
SA256544QC_3QC
SA256545QC_2QC
SA256546QC_1_2QC
SA256547QC_4QC
SA256548QC_2_2QC
SA256549QC_2_3QC
SA256550QC_5QC
SA256551QC_4_2QC
SA256552QC_5_3QC
SA256553QC_5_4QC
SA256554QC_4_3QC
SA256555QC_5_2QC
SA256556SZ26SZ
SA256557SZ25SZ
SA256558SZ24SZ
SA256559SZ27SZ
SA256560SZ30SZ
SA256561SZ23SZ
SA256562SZ29SZ
SA256563SZ28SZ
SA256564SZ08SZ
SA256565SZ06SZ
SA256566SZ07SZ
SA256567SZ09SZ
SA256568SZ10SZ
SA256569SZ05SZ
SA256570SZ04SZ
SA256571SZ01SZ
SA256572SZ02SZ
SA256573SZ03SZ
SA256574SZ11SZ
SA256575SZ12SZ
SA256576SZ18SZ
SA256577SZ19SZ
SA256578SZ20SZ
SA256579SZ21SZ
SA256580SZ17SZ
SA256581SZ16SZ
SA256582SZ13SZ
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 103

Collection:

Collection ID:CO002647
Collection Summary:Blood samples of all subjects were collected in EDTA-coated tubes (BD Vacuntainer®, Becton Dickinson, Franklin Lakes, USA) for plasma metabolite determination after 8 hours of fasting. Samples were centrifuged at 20 °C at 1800 g for 15 minutes and were were stored at -80 ºC prior to lipid extraction.
Sample Type:Blood (plasma)
Storage Conditions:-80℃

Treatment:

Treatment ID:TR002666
Treatment Summary:The study was conducted at the Institute of Psychiatry, University of Sao Paulo, Brazil. The sample consisted of 60 drug-naïve patients (30 SZ and 30 BD) and 30 healthy controls (CT). All participants were under 60 years old and were middle-income, community-dwelling subjects from the hospital catchment area. SZ diagnosis was established according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (Bell, 1994) and SCID-I/P-Structured Clinical Interview Disorders Axis I for DSM-IV version 2.0 (First, 1997) was used to confirm the diagnosis. Psychopathology was assessed using the Positive and Negative Symptoms Scale (PANSS) (Kay et al., 1987) including the positive and negative subscales and general psychopathology. Depressive and manic symptoms were assessed for BD patients by the Hamilton Depression Rating Scale (HAM-D) (Hamilton, 1960) and Young's Mania Rating Scale (YMRS) (Young et al., 1978). Subjects with other psychiatric or neurological disorders were excluded. References cited: Bell, C.C. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. JAMA 1994, 272, 828–829. Spitzer, M.; Robert, L.; Gibbon, M.; Williams, J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute 2002. Kay, S.R.; Fiszbein, A.; Opler, L.A. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull 1987, 13, 261–276. Hamilton, M. A RATING SCALE FOR DEPRESSION. J Neurol Neurosurg Psychiatry 1960, 23, 56–62.
Human Fasting:8 h

Sample Preparation:

Sampleprep ID:SP002660
Sampleprep Summary:Plasma lipids were extracted using the SIMPLEX method (Coman et al., 2016, DOI: 10.1074/mcp.m115.053702). Briefly, the plasma samples were incubated with cold methanol and MTBE, followed by the addition of a 0.1% (m/v) ammonium acetate solution to induce phase separation. The supernatant con-taining lipids, was collected and the solvents were removed with a vacuum concentrator (Eppendorf, Hamburg, Germany). The microtubes with the extracted lipids were stored at -80 ºC prior to UHPLC-MS analysis.
Extraction Method:Simultaneous Metabolite, Protein, Lipid Extraction (SIMPLEX)
Extract Storage:-80℃

Combined analysis:

Analysis ID AN004205
Analysis type MS
Chromatography type Reversed phase
Chromatography system UltiMate 3000 UHPLC system (Thermo Fisher Scientific)
Column ACQUITY CSH C18 (2.1 ⨯ 100 mm, 1.7 μm) column (Waters)
MS Type ESI
MS instrument type Orbitrap
MS instrument name Thermo Q Exactive Orbitrap
Ion Mode NEGATIVE
Units Intensity

Chromatography:

Chromatography ID:CH003116
Chromatography Summary:Ultra-high performance liquid chromatography coupled to mass spectrometry (UHPLC-MS) analyses were performed on an UltiMate 3000 UHPLC system (Thermo Fisher Scientific, Waltham, MA, USA) coupled to a QExactive Orbitrap mass spectrometer (Thermo Fisher Scientific). The chromatographic separation was done on an ACQUITY CSH C18 (2.1 ⨯ 100 mm, 1.7 μm) column (Waters, Milford, MA, USA) and the temperature of the column oven was set to 55 ºC. The mobile phase A consisted of an ACN:water mixture (60:40) with 1 mmol/L ammonium formate and 0.1% (v/v) formic acid, and the mobile phase B consisted of an IPA:ACN mixture (90:10) with 1 mmol/L ammonium formate and 0.1% (v/v) formic acid. The flow rate was 0.4 mL/min and the injection volume was 5 μL for each sample. The gradient elution program consisted of a first linear gradient from solvent (A/B: 60/40) to solvent (A/B: 57/43) over 2 min; a rapid increase to solvent (A/B: 50/50); a second linear gradient to solvent (A/B: 46/54) over 10 min; a rapid increase to solvent (A/B: 30/70); a third linear gradient to solvent (A/B: 1/99) over 6 min; a rapid de-crease to solvent (A/B: 60/40); and finally, an isocratic elution of the solvent (A/B: 60/40) for 2 min. The column was equilibrated with solvent (A/B: 60/40) for 5 min before reuse. The total run time was 25 min for each analysis. Samples were randomized prior to analysis. To verify system stability, quality control (QC) samples were injected at the start and at the end of a run and after every 10th sample.
Instrument Name:UltiMate 3000 UHPLC system (Thermo Fisher Scientific)
Column Name:ACQUITY CSH C18 (2.1 ⨯ 100 mm, 1.7 μm) column (Waters)
Column Temperature:55
Flow Gradient:Gradient elution program (view Summary)
Flow Rate:0.4 mL/min
Sample Injection:5 μL
Solvent A:60% acetonitrile/40% water; 1 mM ammonium formate; 0.1% formic acid
Solvent B:90% isopropanol/10% acetonitrile; 1mM ammonium formate; 0.1% formic acid
Chromatography Type:Reversed phase

MS:

MS ID:MS003952
Analysis ID:AN004205
Instrument Name:Thermo Q Exactive Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:MS scans were acquired in electrospray ionization (ESI) negative mode from m/z 100 to 1500 with a resolution of 70,000. MS target values and maximum injection time were 3 ⨯ 106 ions and 200 ms, respectively. The .raw files were converted to .mzML with the MSConvert software (ProteoWizard, Palo Alto, CA, USA). Using RStudio (RStudio, Boston, MA, USA), the parameters for data processing with the ‘xcms’ package were optimized with the ‘IPO’ package based on QC samples. With the optimized parameters, all the files were processed with ‘xcms’ and, afterwards, the data were organized in a peak list with the ‘CAMERA’ package, followed by the median fold change normalization.
Ion Mode:NEGATIVE
  logo